ΔE1 and high-capacity adenoviral vectors expressing full-length codon-optimized merozoite surface protein 1 for vaccination against Plasmodium falciparum

Journal of Gene Medicine

Volumn 13, Issue 12, 2011, Pages 670-679

  Zong, Shan ^a   Kron, Matthias W ^a   Epp, Christian ^b   Engler, Tatjana ^a   Bujard, Hermann ^c   Kochanek, Stefan ^a   Kreppel, Florian ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

E1 adenoviral vector; Full length codon optimized merozoite surface protein 1 (MSP 1); High capacity adenoviral vector; Malaria; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; BETA ACTIN; GAMMA INTERFERON; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DOSE ESCALATION; FEASIBILITY STUDY; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTIBODY SPECIFICITY; CD8-POSITIVE T-LYMPHOCYTES; CODON; FEMALE; GENETIC VECTORS; HUMANS; INTERFERON-GAMMA; MALARIA, FALCIPARUM; MEROZOITE SURFACE PROTEIN 1; MICE; MICE, INBRED BALB C; PLASMODIUM FALCIPARUM; PROMOTER REGIONS, GENETIC; VACCINES, ADENOVIRUS;

EID: 84255163095     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1627     Document Type: Article

References (41)

1. Blackman MJ, Whittle H, Holder AA. Processing of the Plasmodium falciparum major merozoite surface protein-1: identification of a 33-kilodalton secondary processing product which is shed prior to erythrocyte invasion. Mol Biochem Parasitol 1991; 49: 35-44.
2. Holder AA. The precursor to major merozoite surface antigens: structure and role in immunity. Prog Allergy 1988; 41: 72-97.
3. Kauth CW, Woehlbier U, Kern M, et al. Interactions between merozoite surface proteins 1, 6, and 7 of the malaria parasite Plasmodium falciparum. J Biol Chem 2006; 281: 31517-31527.
4. Stafford WH, Gunder B, Harris A, et al. A 22 kDa protein associated with the Plasmodium falciparum merozoite surface protein-1 complex. Mol Biochem Parasitol 1996; 80: 159-169.
5. Trucco C, Fernandez-Reyes D, Howell S, et al. The merozoite surface protein 6 gene codes for a 36 kDa protein associated with the Plasmodium falciparum merozoite surface protein-1 complex. Mol Biochem Parasitol 2001; 112: 91-101.
6. Goel VK, Li X, Chen H, et al. Band 3 is a host receptor binding merozoite surface protein 1 during the Plasmodium falciparum invasion of erythrocytes. Proc Natl Acad Sci USA 2003; 100: 5164-5169.
7. O'Donnell RA, Saul A, Cowman AF, et al. Functional conservation of the malaria vaccine antigen MSP-119across distantly related Plasmodium species. Nat Med 2000; 6: 91-95.
8. Blackman MJ, Scott-Finnigan TJ, Shai S, et al. Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein. J Exp Med 1994; 180: 389-393.
9. Angov E, Aufiero BM, Turgeon AM, et al. Development and pre-clinical analysis of a Plasmodium falciparum merozoite surface protein-1 (42) malaria vaccine. Mol Biochem Parasitol 2003; 128: 195-204.
10. Singh S, Kennedy MC, Long CA, et al. Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1. Infect Immun 2003; 71: 6766-6774.
11. Chang SP, Case SE, Gosnell WL, et al. A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Infect Immun 1996; 64: 253-261.
12. Kumar S, Yadava A, Keister DB, et al. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Mol Med 1995; 1: 325-332.
13. Siddiqui WA, Tam LQ, Kramer KJ, et al. Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria. Proc Natl Acad Sci USA 1987; 84: 3014-3018.
14. Woehlbier U, Epp C, Kauth CW, et al. Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite Plasmodium falciparum. Infect Immun 2006; 74: 1313-1322.
15. Krzych U, Lyon JA, Jareed T, et al. T lymphocytes from volunteers immunized with irradiated Plasmodium falciparum sporozoites recognize liver and blood stage malaria antigens. J Immunol 1995; 155: 4072-4077.
16. Carralot JP, Lemmel C, Stevanovic S, et al. Mass spectrometric identification of an HLA-A*0201 epitope from Plasmodium falciparum MSP-1. Int Immunol 2008; 20: 1451-1456.
17. Burghaus PA, Gerold P, Pan W, et al. Analysis of recombinant merozoite surface protein-1 of Plasmodium falciparum expressed in mammalian cells. Mol Biochem Parasitol 1999; 104: 171-183.
18. Pan W, Ravot E, Tolle R, et al. Vaccine candidate MSP-1 from Plasmodium falciparum: a redesigned 4917bp polynucleotide enables synthesis and isolation of full-length protein from Escherichia coli and mammalian cells. Nucleic Acids Res 1999; 27: 1094-1103.
19. Epp C, Kauth CW, Bujard H, et al. Expression and purification of Plasmodium falciparum MSP-1 (42): A malaria vaccine candidate. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 786: 61-72.
20. Kauth CW, Epp C, Bujard H, et al. The merozoite surface protein 1 complex of human malaria parasite Plasmodium falciparum: interactions and arrangements of subunits. J Biol Chem 2003; 278: 22257-22264.
21. Draper SJ, Goodman AL, Biswas S, et al. Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria. Cell Host Microbe 2009; 5: 95-105.
22. Draper SJ, Moore AC, Goodman AL, et al. Effective induction of high-titer antibodies by viral vector vaccines. Nat Med 2008; 14: 819-821.
23. Bruder JT, Stefaniak ME, Patterson NB, et al. Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth. Vaccine 2010; 28: 3201-3210.
24. Goodman AL, Epp C, Moss D, et al. New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1. Infect Immun 2010; 78: 4601-4612.
25. Schirmbeck R, Reimann J, Kochanek S, et al. The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens. Mol Ther 2008; 16: 1609-1616.
26. Weaver EA, Nehete PN, Buchl SS, et al. Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines. PLoS One 2009; 4: e5059.
27. Schiedner G, Hertel S, Kochanek S. Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production. Hum Gene Ther 2000; 11: 2105-2116.
28. Palmer D, Ng P. Improved system for helper-dependent adenoviral vector production. Mol Ther 2003; 8: 846-852.
29. Kreppel F, Biermann V, Kochanek S, et al. A DNA-based method to assay total and infectious particle contents and helper virus contamination in high-capacity adenoviral vector preparations. Hum Gene Ther 2002; 13: 1151-1156.
30. Rammensee H, Bachmann J, Emmerich NP, et al. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50: 213-219.
31. Wortmann A, Vohringer S, Engler T, et al. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol Ther 2008; 16: 154-162.
32. Chung S, Andersson T, Sonntag KC, et al. Analysis of different promoter systems for efficient transgene expression in mouse embryonic stem cell lines. Stem Cells 2002; 20: 139-145.
33. Sawicki JA, Morris RJ, Monks B, et al. A composite CMV-IE enhancer/beta-actin promoter is ubiquitously expressed in mouse cutaneous epithelium. Exp Cell Res 1998; 244: 367-369.
34. Harui A, Roth MD, Kiertscher SM, et al. Vaccination with helper-dependent adenovirus enhances the generation of transgene-specific CTL. Gene Ther 2004; 11: 1617-1626.
35. Holst PJ, Orskov C, Thomsen AR, et al. Quality of the transgene-specific CD8+ T cell response induced by adenoviral vector immunization is critically influenced by virus dose and route of vaccination. J Immunol 2010; 184: 4431-4439.
36. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8: 247-258.
37. Suhrbier A, Holder AA, Wiser MF, et al. Expression of the precursor of the major merozoite surface antigens during the hepatic stage of malaria. Am JTrop Med Hyg 1989; 40: 351-355.
38. Kawabata Y, Udono H, Honma K, et al. Merozoite surface protein 1-specific immune response is protective against exoerythrocytic forms of Plasmodium yoelii. Infect Immun 2002; 70: 6075-6082.
39. Imai T, Shen J, Chou B, et al. Involvement of CD8+ T cells in protective immunity against murine blood-stage infection with Plasmodium yoelii 17XL strain. Eur J Immunol 2010; 40: 1053-1061.
40. Garg S, Oran AE, Hon H, et al. The hybrid cytomegalovirus enhancer/chicken beta-actin promoter along with woodchuck hepatitis virus posttranscriptional regulatory element enhances the protective efficacy of DNA vaccines. J Immunol 2004; 173: 550-558.
41. Gribaudo G, Ravaglia S, Caliendo A, et al. Interferons inhibit onset of murine cytomegalovirus immediate-early gene transcription. Virology 1993; 197: 303-311.